Skip to Content
Merck
All Photos(2)

Documents

59353-U

Supelco

Discovery® C8 (5 µm) HPLC Columns

L × I.D. 15 cm × 4.6 mm, HPLC Column

Synonym(s):

C8 Reversed-Phase Chromatography Column

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52

product name

Discovery® C8 HPLC Column, 5 μm particle size, L × I.D. 15 cm × 4.6 mm

material

stainless steel column

Agency

suitable for USP L7

product line

Discovery®

feature

endcapped

manufacturer/tradename

Discovery®

packaging

1 ea of

extent of labeling

7.5% Carbon loading

parameter

≤70 °C temp. range
400 bar pressure (5801 psi)

technique(s)

HPLC: suitable
LC/MS: suitable

L × I.D.

15 cm × 4.6 mm

surface area

200 m2/g

surface coverage

3.4 μmol/m2

impurities

<10 ppm metals

matrix

silica gel, high purity, spherical base material
fully porous particle

matrix active group

C8 (octyl) phase

particle size

5 μm

pore size

180 Å

operating pH range

2-8

application(s)

food and beverages

separation technique

reversed phase

Looking for similar products? Visit Product Comparison Guide

Application

Discovery® C8 HPLC column has been used in the separation of fluoroquinolone antibiotics in tablets using reversed-phase high-performance liquid chromatography (RP-HPLC).

Features and Benefits

  • Excellent reproducibility
  • Faster separation of strongly hydrophobic analytes than C18 columns
  • Stable, low-bleed LC-MS separations
  • Exceptional peak shapes for basic and acidic compounds
  • Compatible with low organic/highly aqueous mobile phases

Legal Information

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
292563-06
292563-05
292563-04
292563-03
292563-02

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Laurence Conraux et al.
PloS one, 8(11), e79733-e79733 (2013-11-14)
The diagnostic of Amyotrophic lateral sclerosis (ALS) remains based on clinical and neurophysiological observations. The actual delay between the onset of the symptoms and diagnosis is about 1 year, preventing early inclusion of patients into clinical trials and early care
Rahul Palchaudhuri et al.
Cell reports, 13(9), 2027-2036 (2015-12-15)
Apoptosis is generally believed to be a process that requires several hours, in contrast to non-programmed forms of cell death that can occur in minutes. Our findings challenge the time-consuming nature of apoptosis as we describe the discovery and characterization
Stefania Butini et al.
The Journal of organic chemistry, 73(21), 8458-8468 (2008-10-11)
A promising way to interfere with biological processes is through the modulation of protein-protein interactions by means of small molecules acting as peptidomimetics. The 1,4-benzodiazepine scaffold has been widely reported as a peptide-mimicking, pharmacogenic system. While several synthetic pathways to
T Mazzei et al.
The Journal of antimicrobial chemotherapy, 31 Suppl C, 1-9 (1993-03-01)
After the discovery of erythromycin and other natural compounds, including oleandomycin, spiramycin, josamycin and midecamycin, much research has been devoted to synthesizing derivatives or analogues with improved chemical, biological and pharmacokinetic properties. These new macrolides are semisynthetic molecules that differ
Scott C Bell et al.
Pharmacology & therapeutics, 145, 19-34 (2014-06-17)
With the discovery of the CFTR gene in 1989, the search for therapies to improve the basic defects of cystic fibrosis (CF) commenced. Pharmacological manipulation provides the opportunity to enhance CF transmembrane conductance regulator (CFTR) protein synthesis and/or function. CFTR
View All Related Papers

Protocols

Separations of Tetracycline Antibiotics by Reversed Phase HPLC, Using Discovery Columns

Separations of Tetracycline Antibiotics by Reversed Phase HPLC, Using Discovery Columns

Related Content

Discovery C18 and C8 HPLC Columns

Discovery C18 and C8 HPLC Columns products offered

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service